In the field of healthcare, June 2023 was filled with significant developments. The US Food and Drug Administration (FDA) made several approvals that garnered attention. Firstly, ferric carboxymaltose injection (INJECTAFER®) was approved for the treatment of iron deficiency in adult patients with heart failure. This marked the first intravenous iron replacement therapy for this indication. The approval was based on data from the CONFIRM-HF trial, which demonstrated the therapy’s efficacy in improving exercise capacity. Secondly, mavacamten (Camzyos) received an updated label to reflect its ability to reduce the need for septal reduction therapy in patients with obstructive hypertrophic cardiomyopathy (HCM). The approval was supported by findings from the VALOR-HCM study. Lastly, colchicine tablets (Lodoco) were approved for reducing cardiovascular risk in patients with established atherosclerotic disease or multiple risk factors. This marked a historic approval as it was the FDA’s first for an anti-inflammatory atheroprotective cardiovascular treatment. In addition to these FDA approvals, two studies stood out in June. A meta-analysis of 13 trials highlighted the benefits of SGLT2 inhibitors in populations with heart failure, type 2 diabetes, and chronic kidney disease. The use of SGLT2 inhibitors reduced the risk of heart failure hospitalization and/or cardiovascular death across these populations. Another study focused on bempedoic acid and its potential role in primary prevention for individuals with statin intolerance. Results from a subgroup analysis within the CLEAR Outcomes trial showed that bempedoic acid was associated with a 30% reduction in relative risk of primary endpoint events. Overall, June 2023 brought forth significant advancements in healthcare, ranging from FDA approvals to insightful studies on various treatments and their impact on patient outcomes.

To know more: About the original article click here.